Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Overview of attention for article published in New England Journal of Medicine, December 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 80 news outlets
blogs: 7 blogs
policy: 4 policy sources
twitter: 338 X users
patent: 136 patents
facebook: 15 Facebook pages

googleplus: 2 Google+ users
reddit: 6 Redditors
q&a: 1 Q&A thread
video: 1 YouTube creator
guideline: 12 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 3470 Mendeley
citeulike: 3 CiteULike

So far, Altmetric has seen 19 public wall posts from 15 users.

Drgios world, 18 Jun 2018

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell…

Internet Medical Association, 17 Jan 2018

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. Clinical Trial, Phase II…

Tom Heston MD, 16 Jan 2018

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. Clinical Trial, Phase II…

Blood and Hematology, 03 Jan 2018

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 15 additional Facebook posts.